- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07519265
Bioekvivalensstudie av Chiglitazar/Metformin förlängd frisättningstabletter
Bioekvivalensstudie av Chiglitazar/Metformin förlängd frisättning fixerad dos kombinationstabletter i friska försökspersoner: En randomiserad, öppen, tvåperiodig, enkeldos, korsningsstudie under matade förhållanden
This is a single-center, randomized, open-label, two-period, two-sequence crossover bioequivalence study under fed conditions. The primary objective is to evaluate the bioequivalence of a single oral dose of the test formulation compared with the reference formulation in the fed state.
Studieöversikt
Status
Betingelser
Intervention / Behandling
- Läkemedel: Chiglitazar/Metformin extended-release fixed-dose combination tablet, dose 1
- Läkemedel: Chiglitazar tablet, dose 1
- Läkemedel: Metformin extended-release tablet, dose 1
- Läkemedel: Chiglitazar/Metformin extended-release fixed-dose combination tablet, dose 2
- Läkemedel: Chiglitazar tablet, dose 2
- Läkemedel: Metformin extended-release tablet, dose 2
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina, 101300
- Beijing Ditan Hospital, Capital Medical University
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Healthy male or female participants;
- Age from 18 to 45 years, inclusive;
- Body Mass Index (BMI) between 19.0 and 26.0 kg/m² (inclusive). Male participants must weigh at least 50.0 kg, and female participants must weigh at least 45.0 kg;
- From the time of signing the informed consent form until 3 months after the last dose, participants must have no plans for pregnancy or sperm donation and must be willing to use effective contraceptive measures;
- Voluntarily agrees to participate in the study and signs the informed consent form.
Exclusion Criteria:
- Any clinically significant abnormalities in laboratory tests or a history of clinically significant diseases, including but not limited to cardiovascular, cerebrovascular, hepatic, renal, respiratory, gastrointestinal, neurological, hematological, immune, oncological, psychiatric, or endocrine/metabolic disorders;
- Known history of severe allergies (e.g., allergy to more than 3 allergens, allergies affecting the lower respiratory tract such as allergic asthma, allergies requiring glucocorticoid treatment) or a known history of allergy to any component of the investigational products;
- Previous surgery that could affect drug absorption, distribution, metabolism, or excretion (e.g., subtotal gastrectomy), or a history of gastrointestinal, hepatic, or renal disease within the last 6 months that could affect drug absorption or metabolism;
- Surgery within 3 months prior to screening or planned surgery during the study period;
- Received any vaccination within 1 month prior to screening or plan to receive any vaccination during the study period;
- History of infectious disease treated with significant use of antibiotics within 3 months before the first dose, or any infectious disease within 7 days before the first dose;
- Presence of gastrointestinal symptoms (e.g., diarrhea, constipation, nausea, vomiting) within 7 days before the first dose, which the investigator deems unsuitable for study participation;
- Use of any prescription drugs, over-the-counter drugs, or Chinese herbal medicines within 1 month before the first dose; or use of vitamin products within 2 weeks before enrollment;
- History of drug or substance abuse, or a positive alcohol or urine drug screening test;
- Intolerance to venipuncture, or a history of fainting in response to needles or blood;
- Fasting blood glucose > 6.1 mmol/L or < 3.9 mmol/L at screening, and/or a history of hypoglycemia/syncope;
- Participation in any interventional clinical trial within 3 months prior to screening;
- Blood donation or significant blood loss (> 200 mL) within 3 months prior to screening;
- Pregnant or lactating women;
- Weekly alcohol consumption of more than 14 units within 3 months prior to screening, consumption of alcohol within 48 hours before the first dose, or inability to abstain from alcohol during the study;
- Smokes more than 5 cigarettes per day within 3 months prior to screening, has smoked within 48 hours before the first dose, or is unable to abstain from smoking during the study;
- Excessive daily consumption of tea, coffee, and/or caffeinated beverages within 3 months prior to screening, or consumption of such beverages within 48 hours before the first dose;
- Consumption of grapefruit or grapefruit-related citrus fruits (e.g., Seville oranges, pomelos), star fruit, papaya, pomegranate, or their products within 14 days before the first dose;
- Glomerular Filtration Rate (GFR) < 90 mL/min/1.73 m²;
- Systolic blood pressure < 90 mmHg or ≥ 140 mmHg, or diastolic blood pressure < 50 mmHg or ≥ 90 mmHg at screening;
- A positive test result at screening for any of the following: Human Immunodeficiency Virus antibody, Treponema pallidum antibody, Hepatitis B surface antigen, or Hepatitis C virus antibody;
- Inability to comply with the standardized diet (e.g., intolerance to the high-fat meal, lactose intolerance) or has difficulty swallowing;
- Plans to or is required to engage in strenuous physical activity or exercise during the study period;
- Any other condition that, in the opinion of the investigator, makes the participant unsuitable for inclusion in the study.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Crossover tilldelning
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Sequence T-R (dose 1)
Participants will receive Chiglitazar/Metformin extended-release fixed dose combination tablets at dose level 1 in Period 1 on Day 1, followed by Chiglitazar tablets and Metformin extended-release tablets at dose level 1 in Period 2 on Day 1. |
Fixed-dose combination tablet containing chiglitazar and metformin extended-release, administered at dose level 1. Chiglitazar tablet administered as one of the reference treatment at dose level 1. Metformin extended-release tablet administered as one of the reference treatment at dose level 1. |
|
Experimentell: Sequence R-T (dose 1)
Participants receive chiglitazar tablet and metformin extended-release tablet at dose level 1 in Period 1 on Day 1, followed by chiglitazar/metformin extended-release fixed-dose combination tablet at dose level 1 in Period 2 on Day 1. |
Fixed-dose combination tablet containing chiglitazar and metformin extended-release, administered at dose level 1. Chiglitazar tablet administered as one of the reference treatment at dose level 1. Metformin extended-release tablet administered as one of the reference treatment at dose level 1. |
|
Experimentell: Sequence T-R (dose 2)
Participants receive chiglitazar/metformin extended-release fixed-dose combination tablet at dose level 2 in Period 1 on Day 1, followed by chiglitazar tablet and metformin extended-release tablet at dose level 2 in Period 2 on Day 1. |
Fixed-dose combination tablet containing chiglitazar and metformin extended-release, administered at dose level 2. Chiglitazar tablet administered as one of the reference treatment at dose level 2. Metformin extended-release tablet administered as one of the reference treatment at dose level 2. |
|
Experimentell: Sequence R-T (dose 2)
Participants receive chiglitazar tablet and metformin extended-release tablet at dose level 2 in Period 1 on Day 1, followed by chiglitazar/metformin extended-release fixed-dose combination tablet at dose level 2 in Period 2 on Day 1. |
Fixed-dose combination tablet containing chiglitazar and metformin extended-release, administered at dose level 2. Chiglitazar tablet administered as one of the reference treatment at dose level 2. Metformin extended-release tablet administered as one of the reference treatment at dose level 2. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Maximal plasmakoncentration (Cmax)
Tidsram: Före dos och vid flera tidpunkter efter dos upp till 72 timmar
|
Före dos och vid flera tidpunkter efter dos upp till 72 timmar
|
|
Area Under the Plasma Concentration-Time Curve from time zero to the last measurable concentration (AUC0-last)
Tidsram: Före dosering och vid flera tidpunkter efter dosering upp till 72 timmar
|
Före dosering och vid flera tidpunkter efter dosering upp till 72 timmar
|
|
Area Under the Plasma Concentration-Time Curve from time zero to infinity (AUC0-∞)
Tidsram: Pre-dos och vid flera tidpunkter efter dosering upp till 72 timmar
|
Pre-dos och vid flera tidpunkter efter dosering upp till 72 timmar
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Tid till maximal plasmakoncentration (Tmax)
Tidsram: För dosering och vid flera tidpunkter efter dosering upp till 72 timmar
|
För dosering och vid flera tidpunkter efter dosering upp till 72 timmar
|
|
Eliminationshalveringstid (t1/2)
Tidsram: Pre-dos och vid flera tidpunkter efter dosering upp till 72 timmar
|
Pre-dos och vid flera tidpunkter efter dosering upp till 72 timmar
|
|
Skensk Total Clearance (CL/F)
Tidsram: Före dosering och vid flera tidpunkter efter dosering upp till 72 timmar
|
Före dosering och vid flera tidpunkter efter dosering upp till 72 timmar
|
|
Uppenbart distributionsvolym under terminalfasen (Vz/F)
Tidsram: Före dos och vid flera tidpunkter efter dos upp till 72 timmar
|
Före dos och vid flera tidpunkter efter dos upp till 72 timmar
|
|
Förekomst av biverkningar (AEs)
Tidsram: upp till dag 11
|
upp till dag 11
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- CGZ112
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .